These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

925 related articles for article (PubMed ID: 20797569)

  • 1. Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease.
    Vaziri ND
    J Ren Nutr; 2010 Sep; 20(5 Suppl):S35-43. PubMed ID: 20797569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid disorders and their relevance to outcomes in chronic kidney disease.
    Vaziri ND; Norris K
    Blood Purif; 2011; 31(1-3):189-96. PubMed ID: 21228589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease.
    Moradi H; Pahl MV; Elahimehr R; Vaziri ND
    Transl Res; 2009 Feb; 153(2):77-85. PubMed ID: 19138652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid and lipoprotein metabolism in chronic kidney disease.
    Kaysen GA
    J Ren Nutr; 2009 Jan; 19(1):73-7. PubMed ID: 19121776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice: LCAT gene transfer decreases atherosclerosis.
    Mertens A; Verhamme P; Bielicki JK; Phillips MC; Quarck R; Verreth W; Stengel D; Ninio E; Navab M; Mackness B; Mackness M; Holvoet P
    Circulation; 2003 Apr; 107(12):1640-6. PubMed ID: 12668499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences.
    Vaziri ND
    Am J Physiol Renal Physiol; 2006 Feb; 290(2):F262-72. PubMed ID: 16403839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HDL metabolism and activity in chronic kidney disease.
    Vaziri ND; Navab M; Fogelman AM
    Nat Rev Nephrol; 2010 May; 6(5):287-96. PubMed ID: 20308998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic syndrome and renal failure: similarities and differences.
    Kaysen GA
    Panminerva Med; 2006 Sep; 48(3):151-64. PubMed ID: 17122751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis.
    Kontush A; Chapman MJ
    Pharmacol Rev; 2006 Sep; 58(3):342-74. PubMed ID: 16968945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-density lipoproteins, inflammation and oxidative stress.
    Tabet F; Rye KA
    Clin Sci (Lond); 2009 Jan; 116(2):87-98. PubMed ID: 19076062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of oral contraceptives on lipid metabolism.
    Krauss RM
    J Reprod Med; 1986 Jun; 31(6 Suppl):549-50. PubMed ID: 3723487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disorders in high-density metabolism with insulin resistance and chronic kidney disease.
    Kaysen GA
    J Ren Nutr; 2007 Jan; 17(1):4-8. PubMed ID: 17198924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High lipid levels in very low density lipoprotein and intermediate density lipoprotein may cause proteinuria and glomerulosclerosis in aging female analbuminemic rats.
    Joles JA; van Goor H; van der Horst ML; van Tol A; Elema JD; Koomans HA
    Lab Invest; 1995 Dec; 73(6):912-21. PubMed ID: 8558854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of dietary oxidized cholesterol and oxidized fatty acids in the development of atherosclerosis.
    Staprans I; Pan XM; Rapp JH; Feingold KR
    Mol Nutr Food Res; 2005 Nov; 49(11):1075-82. PubMed ID: 16270280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Niacin ameliorates oxidative stress, inflammation, proteinuria, and hypertension in rats with chronic renal failure.
    Cho KH; Kim HJ; Rodriguez-Iturbe B; Vaziri ND
    Am J Physiol Renal Physiol; 2009 Jul; 297(1):F106-13. PubMed ID: 19420110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Causes of dysregulation of lipid metabolism in chronic renal failure.
    Vaziri ND
    Semin Dial; 2009; 22(6):644-51. PubMed ID: 20017835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statins and renal diseases: from primary prevention to renal replacement therapy.
    D'Amico G
    J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S148-52. PubMed ID: 16565241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease.
    Chapman MJ
    Pharmacol Ther; 2006 Sep; 111(3):893-908. PubMed ID: 16574234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current understanding of the role of high-density lipoproteins in atherosclerosis and senescence.
    Nofer JR; Walter M; Assmann G
    Expert Rev Cardiovasc Ther; 2005 Nov; 3(6):1071-86. PubMed ID: 16292998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.